Therapy News and Research

RSS

Circadian initiates VGX-100 Phase 1 trial in advanced solid tumours

Circadian Technologies Limited announced today that it has commenced the first Phase 1 clinical trial of its fully human monoclonal antibody against VEGF-C, VGX-100, at a leading US-based cancer treatment centre.

9 Jan 2012

AICAR therapy may combat heat stroke

We've all seen the story in the news before. Whether it's the death of a physically fit high school athlete at football training camp in August, or of an elderly woman gardening in the middle of the day in July, heat stroke is a serious, life-threatening condition for which there is no treatment beyond submersion in ice water or the application of ice packs to cool the body to a normal temperature.

8 Jan 2012

Scientists develop simple, reliable test to identify biomarkers for MPS

A team of scientists, led by researchers at the University of California, San Diego School of Medicine and Zacharon Pharmaceuticals, have developed a simple, reliable test for identifying biomarkers for mucopolysaccharidoses (MPS), a group of inherited metabolic disorders that are currently diagnosed in patients only after symptoms have become serious and the damage possibly irreversible.

8 Jan 2012

Positive results from BioCryst's BCX4208 Phase 2b study on gout

BioCryst Pharmaceuticals, Inc. announced long-term results from the extension phase of its randomized Phase 2b study of BCX4208 added to allopurinol in patients with gout who had failed to reach the serum uric acid (sUA) therapeutic goal of <6 mg/dL on allopurinol alone.

8 Jan 2012

Bristol-Myers Squibb signs definitive agreement to acquire Inhibitex

Bristol-Myers Squibb Company and Inhibitex, Inc. announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger.

8 Jan 2012

Disabled soldier goes back to Walter Reed to deliver Gift Cards to veterans

In a moving scene, the President of The Disabled Veterans National Foundation (www.dvnf.org ) and Michael McNaughton - a combat soldier who lost his leg on a mission in Afghanistan- delivered Gift Cards to veterans who are patients in the amputee wing at Walter Reed National Military Medical Center in Bethesda, MD over the holidays.

7 Jan 2012

Allsup and PRIUM partner to address pharmacy regimens and costs for MSAs

PRIUM and Allsup Medicare Secondary Payer Compliance Services have joined forces to address pharmacy regimens and costs before submitting Medicare Set-Asides to the Centers for Medicare and Medicaid Services.

7 Jan 2012

Cardinal Health launches infusion room management tool for community rheumatologists

Cardinal Health Specialty Solutions today launched InfusaTrack, a Web-based infusion room management tool that makes it easier for community rheumatology practices to offer in-office infusion therapy services to patients.

7 Jan 2012

AABB accredits LABS for donor testing

LABS, Inc., a global, full-service testing laboratory with more than 30 years of expertise in regulated testing for human organs, cells, tissues and implantable biologic products and devices, today announced that it has been granted AABB Accreditation for donor testing.

7 Jan 2012

Smokeless tobacco products in India associated with increased risk of oral cancer

The 2nd International Conference on the Frontiers in Prevention, Diagnosis & Therapy of Cancer was held on 7th Jan. 2012 at Allahabad, India and looked at the relationship of oral cancer with tobacco habits. Various innovations in oral cancer diagnosis, therapy and tobacco usage were discussed by experts from around the world.

7 Jan 2012

Prospective surveillance model can reduce treatment costs for breast cancer-related lymphedema

Early diagnosis and treatment of breast cancer-related lymphedema by a physical therapist can significantly reduce costs and the need for intensive rehabilitation, according to an article published in the January issue of Physical Therapy (PTJ), the scientific journal of the American Physical Therapy Association.

7 Jan 2012

Annual prostate cancer testing does not reduce mortality among men

Men enrolled in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial had no evidence of a mortality benefit compared to a control group of men undergoing usual care, according to a study published online Jan. 6 in the Journal of the National Cancer Institute.

7 Jan 2012

IQWiG study finds considerable added benefit of abiraterone in prostate cancer patients

Abiraterone has been approved since September 2011 for men with metastatic prostate cancer that is no longer responsive to hormone therapy and progresses further during or after therapy with the cytostatic drug docetaxel.

7 Jan 2012

Linagliptin does not offer added benefit for adults with type 2 diabetes

Linagliptin has been approved since August 2011 to improve blood glucose control in adults with type 2 diabetes mellitus whose elevated blood glucose levels are inadequately controlled by diet and exercise.

7 Jan 2012

PCI Biotech focuses on localised cancer therapy with minimum side effects

Side effects are currently the biggest problem with any cancer treatment. A Norwegian biotech company is drawing closer to the goal of creating a treatment which kills only cancer cells, leaving other cells unaffected.

7 Jan 2012

VisionGate achieves full automation of Cell-CT system

VisionGate, Inc., a company developing a revolutionary non-invasive test for the early detection of lung cancer and other applications, today reported that it has achieved full automation of its Cell-CT system, a proprietary imaging platform that generates high-resolution 3D biosignatures from intact cells.

7 Jan 2012

Positive topline results from Civitas' CVT-301 Phase 1 trial on PD

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS(TM) respiratory delivery platform, announced today positive topline results from a Phase 1 clinical trial for CVT-301, an inhaled formulation of levodopa (L-dopa) for the rapid relief from motor fluctuations associated with Parkinson's disease.

7 Jan 2012

Viewpoints: Sebelius on curbing the increase in health insurance costs; Forcing the mentally ill into treatment

The rising cost of health insurance coverage has imposed a heavy burden on our nation. Over the past decade, insurance premiums for working families have grown three times faster than have wages. Small businesses have seen health care become one of their biggest operating expenses. And rising state and federal spending on health programs has crowded out critical investments in better schools, new roads and other areas.

7 Jan 2012

Annual screening tests do not decrease deaths from prostate cancer

There's new evidence that annual prostate cancer screening does not reduce deaths from the disease, even among men in their 50s and 60s and those with underlying health conditions, according to new research led by Washington University School of Medicine in St. Louis.

6 Jan 2012